 MARLBOROUGH, Mass., June 22, 2021 PRNewswire -- Phio Pharmaceuticals Corp. Nasdaq: PHIO, a biotechnology company developing the next generation of immuno-oncology therapeutics based on its proprietary self-delivering RNAi INTASYLTM therapeutic platform, today announced that it has rescheduled the Companys fireside chat being hosted by H.C. 